Keros Faces Stock Plunge, Suspends Two Hypertension Study Arms Due to Heart Safety Concerns

Keros Therapeutics experienced a significant decline in its stock price, dropping over 70% during premarket trading after announcing safety concerns related to its hypertension drug candidate, cibotercept[1]. The biotech company was compelled to suspend dosing in the 3-mg/kg and 4.5-mg/kg arms of its Phase II TROPOS trial due to unexpected cases of pericardial effusion, which is an accumulation of fluid around the heart[2]. This adverse development led to a 65% drop in Keros’ shares as the safety issues prompted immediate concern among investors[2]. Truist Securities analysts predict continued pressure on the stock until these safety concerns are fully addressed, with more data expected by the second quarter of 2025[1].